Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial - Howard, JF, Jr; Bril, V; Vu, T (Lancet Neurol, 2021)
et al.